Microphones_edited.jpg

News & Events

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells

February 16th, 2021

Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors

January 13th, 2021

Watch a replay of the Cell Therapy panel at the 10th Annual LifeSci Partners Corporate Access Event, featuring our CEO Dr. Daniel Teper

January 7th, 2021

Watch a replay of Cytovia's recent fireside chat at the RBC Capital Markets Healthcare Conference, featuring CEO Dr. Daniel Teper and CSO Dr. Wei Li

December 16th, 2020

Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors

December 8th, 2020

Watch Cytovia's recent presentation at the Jefferies London Healthcare Conference, featuring CEO Daniel Teper and CSO Wei Li

November 23rd, 2020

Cytovia Therapeutics to Present at Jefferies Virtual London Healthcare Conference

November 12th, 2020

Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients

October 8th, 2020

Watch Cytovia's recent webinar at the Jefferies Cell Therapy Virtual Summit, featuring CEO Dr. Daniel Teper and CSO Dr. Wei Lu

October 7th, 2020

Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020

September 29th, 2020

Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for the Treatment of Cancer

August 25th, 2020

Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic

August 12th, 2020

Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors

August 3rd, 2020

June 24th, 2020

Learn More

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

Cytovia CEO Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

Hebrew University to Collaborate with Cytovia Therapeutics on Natural Killer Cell Research

March 18th, 2020

Webcast: BIO CEO & Investor Conference

February 12th, 2020

Cytovia CEO interviewed by Proactive

February 11th, 2020

Cytovia's CAR NK Alliance With NYSCF, UCSF Aims to Overcome Negative Side Effects of CAR T Drugs

February 3rd, 2020

Cytovia Therapeutics to present at BIO CEO & Investor Conference

February 3rd, 2020

Cytovia Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics

January 9th, 2020

Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy

January 6th, 2020

Cytovia Therapeutics, Inc. and STC Biologics, Inc. enter into a partnership to develop and manufacture NK cell engager multi-specific antibodies

January 2nd, 2020

Cytovia CEO Dr. Daniel Teper to speak at East/West Conference

December 29th, 2019

October 28th, 2019

Cytovia Therapeutics to Present at 2019 Bio Investor Forum

October 21st, 2019